4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.11
    -0.56 (-3.82%)

    Market Cap: $810.43M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(12/24)
    Avg Surprise
    -26.05%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.04
    Range$-1.09 - $-0.99
    10 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.01+2.9%
    60d ago$-1.01+2.9%
    30d ago$-1.01+2.8%
    7d ago$-1.02+2.2%
    Current$-1.04
    Revenue Consensus
    $3M
    Range$0 - $6M
    8 analysts
    Dec 31, 2026
    EPS Consensus$-1.08
    Range$-1.16 - $-0.94
    9 analysts
    Revenue Consensus
    $4M
    Range$-1662620 - $14M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.08---
    Sep 26EST
    		-$-1.04---
    Jun 26
    		$-1.04$-1.04+0.00%Beat-6.1%
    Mar 26
    		$-1.01$-1.00-1.00%Miss-17.4%
    Dec 25
    		$0.43$-0.53+180.83%Beat+147.8%
    Sep 25
    		$-1.01$-0.98-3.06%Miss-27.8%
    Jun 25
    		$-0.98$-0.69-42.03%Miss-55.6%
    Mar 25
    		$-0.86$-0.86+0.00%Beat-30.3%
    Dec 24
    		$-0.90$-0.84-7.41%Miss-20.0%
    Sep 24
    		$-0.79$-0.70-12.86%Miss-229.2%
    Jun 24
    		$-0.63$-0.71+11.27%Beat+18.2%
    Mar 24
    		$-0.66$-0.76+13.16%Beat+25.0%
    Dec 23
    		$-0.75$-0.74-1.35%Miss+10.7%
    Sep 23
    		$-0.24N/A+60.00%Beat+69.6%
    Jun 23
    		$-0.77$-0.77+0.00%Beat+11.5%
    Mar 23
    		$-0.88$-0.90+2.22%Beat-7.3%
    Dec 22
    		$-0.84$-0.79-6.33%Miss+1.2%
    Sep 22
    		$-0.79$-0.91+13.19%Beat+3.7%
    Jun 22
    		$-0.87$-0.85-2.35%Miss-210.7%
    Mar 22
    		$-0.82$-0.77-6.49%Miss-34.4%
    Dec 21
    		$-0.85$-0.86+1.16%Beat+64.0%
    Sep 21
    		$-0.82$-0.80-2.50%Miss+73.3%
    Jun 21
    		$-0.28N/A+58.82%Beat+91.0%
    Mar 21
    		$-0.61$-1.10+44.55%Beat+66.5%
    Dec 20
    		$-2.36$-0.66-257.58%Miss-46.7%
    Sep 20
    		$-3.07$-0.40-667.50%Miss-90.8%
    Sep 19
    		$-3.12$0.00N/AMiss-626.2%
    Jun 19
    		$-1.82$0.00N/AMiss-323.5%
    Mar 19
    		$-1.61$0.00N/AMiss-211.6%
    Dec 18
    		$-1.61$0.00N/AMiss-211.6%
    Sep 18
    		$-0.43$0.00N/AMiss-
    Jun 18
    		$-0.43$0.00N/AMiss-
    Mar 18
    		$-0.52$0.00N/AMiss-
    Dec 17
    		$-0.52$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-5.37EV/EBITDA-3.55x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-194.70%Operating Margin-2037.00%
    ROE-43.20%ROIC-36.49%
    Financial Health
    Debt/Equity0.05xInterest CoverageN/A
    Current Ratio8.03xQuick Ratio8.03x
    Trading Statistics
    Beta2.69Avg Volume1.06M
    52-Week High$16.9352-Week Low$5.97

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.38
    SMA 20$13.42
    SMA 50$12.23
    SMA 200$10.02
    EMA 10$14.65
    EMA 20$13.82
    EMA 50$12.37
    EMA 200$10.10

    MACD

    Line: 1.08Signal: 1.08Hist: -0.00

    ADX

    ADX: 31.6+DI: 27.7-DI: 21.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down8.0
    PSAR$16.63

    Bollinger Bands

    Upper Band$17.93
    Lower Band$8.92
    %B Position6711%(Upper)
    Band Width0.58

    RSI (14-Day)

    Neutral
    55.9

    Momentum Oscillators

    Stoch %K60.6
    Stoch %D69.0
    Williams %R-49.7
    ROC (10d)-3.0%
    Momentum-0.43
    CCI (20d)25.9
    MFI (14d)52.3

    Volatility Measures

    ATR (14d)$1.01(7.2%)
    StdDev (20d)2.25
    Hist Vol92.0%(High)

    Volume Flow

    VWAP$14.13
    OBV47.0M
    AD Line19.6M
    CMF (20d)0.295

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio1.3x
    VWMA (20d)$14.28

    Pivot Points

    R3$15.85
    R2$15.42
    R1$15.05
    Pivot Point$14.62
    S1$14.25
    S2$13.82
    S3$13.45

    Advanced Oscillators

    TSI31.77
    Ultimate Osc52.8
    KST358.83

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$3.78M$3.05M$85.21M$0$15,000$0$1,000$0$0$0$519,000$20.20M
    Cost of Revenue$0$0$1.98M$0$0$0$1.78M$0$0$0$26.03M$0
    Gross Profit$3.78M$3.05M$85.21M$0$15,000$0$-1,783,000$0$0$0$519,000$20.20M
    Operating Expenses$80.81M$76.67M$70.38M$61.27M$59.47M$53.63M$56.12M$51.13M$42.46M$38.16M$36.63M$34.18M
    R&D$68.28M$64.98M$57.61M$49.44M$47.95M$40.70M$43.09M$38.48M$31.86M$27.87M$26.03M$25.07M
    SG&A$12.52M$11.69M$12.77M$11.84M$11.52M$12.94M$13.03M$12.65M$10.60M$10.29M$10.60M$9.11M
    Operating Income$-77,025,000$-73,620,000$14.71M$-61,185,000$-59,456,000$-53,621,000$-56,117,000$-51,132,000$-42,456,000$-38,136,000$-36,651,000$-13,974,000
    Interest Income$4.25M$4.86M$4.70M$4.33M$4.86M$5.58M$6.47M$7.29M$7.55M$5.75M$4.38M$3.88M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-72,936,000$-68,760,000$19.40M$-56,876,000$-54,658,000$-47,972,000$-49,671,000$-43,843,000$-34,953,000$-32,401,000$-32,283,000$-10,256,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-72,936,000$-68,760,000$19.40M$-56,876,000$-54,658,000$-47,972,000$-49,671,000$-43,843,000$-34,953,000$-32,401,000$-32,283,000$-10,256,000
    EBITDA$-76,092,000$-72,703,000$15.53M$-60,357,000$-58,795,000$-53,067,000$-56,204,000$-51,670,000$-43,212,000$-37,309,000$-35,629,000$-12,886,000
    EBIT$-77,191,000$-73,624,000$14.69M$-61,206,000$-59,517,000$-53,554,000$-56,138,000$-51,133,000$-42,501,000$-38,146,000$-36,663,000$-14,132,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FDMT

    News

    4DMT to Participate in Upcoming Investor Conferences

    4D Molecular Therapeutics (4DMT) announced its participation in three upcoming investor conferences in September 2026: the Wells Fargo 2026 Healthcare Conference, the 2026 Cantor Global Healthcare Conference, and the Morgan Stanley 24th Annual Global Healthcare Conference. Management will present and engage in one-on-one meetings, with a fireside chat scheduled for the Cantor and Morgan Stanley events. Webcasts of these presentations will be archived on the company's investor relations website for one year.

    Yahoo Finance•8/25/26•
    Somewhat-Bullish

    4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan

    David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ: FDMT), exercised stock options for 50,000 shares at $4.14 each and subsequently sold 69,076 common shares in open-market transactions on August 19, 2026. The sales, totaling approximately $1.09 million gross proceeds, were conducted under a Rule 10b5-1 trading plan established on January 9, 2026. After these transactions, Kirn retains 217,500 stock options and 825,819 common shares.

    Stock Titan•8/21/26•
    Somewhat-Bearish

    4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7% - Here's What Happened

    Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) dropped 3.7% on Friday, trading at around $15.50 on lower-than-average volume. Despite a "Moderate Buy" consensus rating and a $29.62 average price target from analysts, the company reported a quarterly loss of $1.04 per share, missing estimates, though revenue exceeded expectations. Insider selling also occurred, with 200,496 shares sold for approximately $2.24 million in the last quarter.

    MarketBeat•8/21/26•
    Somewhat-Bearish

    David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale

    David Kirn, an officer at 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 69,076 shares of Class A Common Stock valued at approximately $1.16 million through Goldman Sachs & Co. LLC. This sale is part of a Rule 10b5-1(c) selling plan initiated on January 9, 2026. The filing indicates previous sales by Kirn and details how the shares were acquired, some through private transactions and others via stock options.

    Stock Titan•8/20/26•
    Neutral

    4D Molecular Therapeutics(FDMT) Stock Options Chain | Quotes & News

    This document appears to be a stub or an empty page for 4D Molecular Therapeutics (FDMT) stock options chain, quotes, and news. It indicates a lack of detailed content, suggesting it might be a placeholder.

    Moomoo•8/19/26•
    Neutral

    Frequently Asked Questions About FDMT

    Does FDMT pay dividends?
    4D Molecular Therapeutics Inc (FDMT) does not currently pay a regular dividend.
    What is FDMT's market cap?
    4D Molecular Therapeutics Inc (FDMT) has a market capitalization of $810.43M with a current stock price of $14.11.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In